Novel protease inhibitor-loaded Nanoparticle-in-Microparticle Delivery System leads to a dramatic improvement of the oral pharmacokinetics in dogs

Biomaterials

Volumn 37, Issue , 2015, Pages 383-394

  Imperiale, Julieta C ^a   Nejamkin, Pablo ^b   del Sole, Maria J ^b   Lanusse, Carlos E ^b,c   Sosnik, Alejandro ^d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DEL CENTRO DE LA PROVINCIA DE BUENOS AIRES   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

HIV infection; Indinavir free base; Mucoadhesion; Oral bioavailability; Protease inhibitors; Pure drug Nanoparticle in Microparticle Delivery System (NiMDS)

Indexed keywords

BIOCHEMISTRY; CONTROLLED DRUG DELIVERY; ENCAPSULATION; ENZYME INHIBITION; NANOPARTICLES; PHARMACOKINETICS;

FREE BASE; HIV INFECTION; MICRO PARTICLES; MUCOADHESION; ORAL BIOAVAILABILITIES; PROTEASE INHIBITOR;

TARGETED DRUG DELIVERY;

ACETONE; ALGINIC ACID; CHITOSAN; EUDRAGIT; INDINAVIR; NANOCRYSTAL; POLYMER; GLUCURONIC ACID; HEXURONIC ACID; NANOPARTICLE; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; EXPERIMENTAL DOG; GAS CHROMATOGRAPHY; GASTROINTESTINAL TRANSIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; INTESTINE MUCOSA; MONGREL DOG; MUCOADHESION; NANOENCAPSULATION; NANOPARTICLE IN MICROPARTICLE DRUG DELIVERY SYSTEM; NANOPRECIPITATION; NONHUMAN; PARTICLE SIZE; POLARIZATION; PRECIPITATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; THERMAL ANALYSIS; THERMOGRAPHY; X RAY DIFFRACTION; ZETA POTENTIAL; ADHESION; ANIMAL; BLOOD; BOVINE; CHEMISTRY; DOG; DOSE RESPONSE; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; TIME; ULTRASTRUCTURE;

BOVINAE; CANIS FAMILIARIS;

ADHESIVENESS; ADMINISTRATION, ORAL; ALGINATES; ANIMALS; CATTLE; CHITOSAN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; GLUCURONIC ACID; HEXURONIC ACIDS; INDINAVIR; NANOPARTICLES; PROTEASE INHIBITORS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TIME FACTORS; X-RAY DIFFRACTION;

EID: 84922254144     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.10.026     Document Type: Article

References (52)

1. HIV/AIDS Fact Sheet #360 World health organization 2014, Available from: URL. http://www.who.int/mediacentre/factsheets/fs360/en/.
2. Global AIDS response progress reporting 2014, UNAIDS 2014, Available from: URL. http://www.unaids.org/es/dataanalysis/knowyourepidemic/.
3. Thompson M.A., Aberg J.A., Hoy J.F., Telenti A., Benson C., Cahn P., et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAm Med Assoc 2012, 308:387-402.
4. Andrews L., Friedland G. Progress in the HIV therapeutics and the challenges of adherence to antiretroviral therapy. Infect Dis Clin North Am 2000, 14:1-26.
5. Nicholson L.K., Yamazaki T., Torchia D.A., Grzesiek S., Bax A., Stahl S.J., et al. Flexibility and function in HIV-1 protease. Nat Struct Biol 1995, 2:274-280.
6. Kumar G.N., Rodrigues A.D., Buko A.M., Denissen J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. JPharmacol Exp Ther 1996, 277:423-431.
7. Ford J., Khoo S.H., Back D.J. The intracellular pharmacology of antiretroviral protease inhibitors. JAntimicrob Chemother 2004, 54:982-990.
8. Hochman J.H., Chiba M., Nishime J., Yamazaki M., Lin J.H. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. JPharmacol Exp Ther 2000, 292:310-318.
9. Lee C.G., Gottesman M.M., Cardarelli C.O., Ramachandra M., Jeang K.T., Ambudkar S.V., et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998, 37:3594-3601.
10. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. JClin Invest 1998, 101:289-294.
11. Profit L., Eagling V.A., Back D.J. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999, 13:1623-1627.
12. Srinivas R.V., Middlema D., Flynn P., Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998, 42:3157-3162.
13. Antiretroviral drugs used in the treatment of HIV infection, US food and drug administration. Available from: URL: http://www.fda.gov/forconsumers/byaudience/%20forpatientadvocates/ucm076940.htm.
14. Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?. Expert Opin Pharmacother 2007, 8:957-964.
15. Cahn P. Dual therapy with lopinavir/ritonavir (LPV/r) and lamivudine (3TC) is non-inferior to standard triple drug therapy in naïve HIV-1 infected subjects: 48-week results of the GARDEL study. 14th European AIDS conference of the European AIDS clinical society 2013, On behalf of the GARDEL Study Group, Belgium, Brussels, Abstract LBPS7/6.
16. Wu C.Y., Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of biopharmaceutics drug disposition classification system. Pharm Res 2005, 22:11-23.
17. Rittweger M., Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007, 46:739-756.
18. Sosnik A., Chiappetta D.A., Carcaboso A.M. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. JControl Release 2009, 138:2-15.
19. Imperiale J.C., Sosnik A. Nanoparticle-in-microparticle delivery systems (NiMDS): production, routes of administration and clinical potential. JBiomater Tissue Eng 2013, 3:22-38.
20. Sosnik A, das Neves J, Sarmento B. Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review. Prog Polym Sci, accepted.
21. Toteva M.M., Zanon R., Ostovic D. Kinetics and mechanism of the hydrolytic degradation of indinavir: intramolecular catalysis. JPharm Sci 2008, 97:3810-3819.
22. Imperiale J.C., Bevilacqua G., de Tarso Vieira e Rosa P., Sosnik A. Production of pure indinavir free base nanoparticles by a supercritical anti-solvent (SAS) method. Drug Dev Ind Pharm 2013, Available from: URL. http://www.ncbi.nlm.nih.gov/pubmed/24050705, 10.3109/03639045.2013.838581.
23. Phillips D.J., Pygall S.R., Cooper B., Mann J.C. Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. JPharm Pharmacol 2012, 64:1549-1559.
24. Shah L.K., Amiji M.M. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res 2006, 23:2638-2645.
25. Glisoni R.J., García-Fernández M.J., Pino M., Gutkind G., Moglioni A., Alvarez-Lorenzo C., et al. β-Cyclodextrin hydrogels for the ocular release of antibacterial thiosemicarbazones. Carbohydr Polym 2013, 93:449-457.
26. Lin J.H., Chen I.W., Vastag K.J., Ostovic D. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos 1995, 23:730-735.
27. Nithitanakool S., Pithayanukul P., Bourgeois S., Fessi H., Bavovada R. The development, physicochemical characterisation and invitro drug release studies of pectinate gel beads containing Thai mango seed kernel extract. Molecules 2013, 18:6504-6520.
28. The United States Pharmacopeia Convention, USP 33/701, Rockville M.D 2008.
29. McMillan C.J., Livingston A., Clark C.R., Dowling P.M., Taylor S.M., Duke T., et al. Pharmacokinetics of intravenous tramadol in dogs. Can J Vet Res 2008, 72:325-331.
30. Bramuglia G.F., Cortada C.M., Curras V., Hocht C., Buontempo F., Mato G., et al. Relationship between P-glycoprotein activity measured in peripheral blood mononuclear cells and indinavir bioavailability in healthy volunteers. JPharm Sci 2009, 98:327-336.
31. Rabinow B.E. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004, 3:785-796.
32. Müller R.H., Gohla S., Keck C.M. State of the art of nanocrystals - special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011, 78:1-9.
33. ® RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz. Colloids Surf B Biointerfaces 2013, 102:441-449.
34. ICH Topic Q3C (R4). Impurities: guideline for residual solvents, European Medicines Agency. Available from: URL: http://www.tga.gov.au/pdf/euguide/ich28395enrev4.pdf.
35. Glisoni R.J., Chiappetta D.A., Finkielsztein L.M., Moglioni A.G., Sosnik A. Self-aggregation behaviour of novel thiosemicarbazone drug candidates with potential antiviral activity. New J Chem 2010, 34:2047-2058.
36. Ferreira da Silva R.M., Morais de Medeiros F.P., Nascimento T.G., Macedo R.O., Neto P.J.R. JTherm Anal Calorim 2009, 95:965-968.
37. Andrade F., Goycoolea F., Chiappetta D.A., das Neves J., Sosnik A., Sarmento B. Chitosan-grafted copolymers and chitosan-ligand conjugates as matrices for pulmonary drug delivery. Int J Carbohyd Chem 2011, 2011. Art. 865704.
38. Sosnik A. Alginate particles as platform for drug delivery by the oral route: State-of-the-Art. ISRN Pharm 2014, 2014. Art. 926157.
39. Pasparakis G., Bouropoulos N. Swelling studies and invitro release of verapamil from calcium alginate and calcium alginate-chitosan beads. Int J Pharm 2006, 323:34-42.
40. Sankalia M.G., Mashru R.C., Sankalia J.M., Sutariya V.B. Reversed chitosan-alginate polyelectrolyte complex for stability improvement of alpha-amylase: optimization and physicochemical characterization. Eur J Pharm Biopharm 2007, 65:215-232.
41. 2+ ions. React Funct Polym 2004, 59:129-140.
42. Dillen K., Vandervoort J., Van den Mooter G., Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm 2006, 314:72-82.
43. Davidovich-Pinhas M., Bianco-Peled H. Mucoadhesion: a review of characterization techniques. Expert Opin Drug Deliv 2010, 7:259-271.
44. Hung S.-F., Hsieh C.-M., Chen Y.-C., Wang Y.-C., Ho H.-O., Sheu M.-T. Characterizations of plasticized polymeric film coatings for preparing multiple-unit floating drug delivery systems (muFDDSs) with controlled-release characteristics. PLOS One 2014, 9:e100321.
45. das Neves J., Bahia M.F., Amiji M.M., Sarmento B. Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. Expert Opin Drug Deliv 2011, 7:1085-1104.
46. Bastakoti B.P., Guragain S., Yokoyama Y., Yusa S., Nakashima K. Incorporation and release behavior of amitriptylene in core-shell-corona type triblock copolymer micelles. Colloids Surf B: Biointerfaces 2011, 88:734-740.
47. Puga A.M., Rico-Rey A., Magariños B., Alvarez-Lorenzo C., Concheiro A. Hot melt poly-ε-caprolactone/poloxamine implantable matrices for sustained delivery of ciprofloxacin. Acta Biomater 2012, 8:1507-1518.
48. Burger D., Boyd M., Duncombe C., Felderhof M., Mahanontharit A., Ruxrungtham K., et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. JAntimicrob Chemother 2003, 51:1231-1238.
49. Glisoni R.J., Sosnik A. Novel poly(ethylene oxide)-co-poly(propylene oxide) copolymer-glucose conjugate by the microwave-assisted ring opening of a sugar lactone. Macromol Biosci 2014, in press. 10.1002/mabi.201400235.
50. Sosnik A., Seremeta K.P., Imperiale J.C., Chiappetta D.A. Novel formulation and drug delivery strategies for the treatment of pediatric poverty related diseases (PRDs). Expert Opin Drug Deliv 2012, 9:303-323.
51. Sosnik A., Carcaboso A. Nanomedicines in the future of pediatric therapy. Adv Drug Deliv Rev 2014, 73:140-161.
52. Chiappetta D.A., Carcaboso A.M., Bregni C., Rubio M.C., Bramuglia G., Sosnik A. Indinavir-loaded ph-sensitive microparticles for taste masking: towards extemporaneous paediatric HIV/AIDS liquid formulations with improved patient compliance. AAPS PharmSciTech 2009, 10:1-6.